Literature DB >> 10656730

Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.

L J Layfield1, K Liu, R Dodge, S H Barsky.   

Abstract

CONTEXT: Accurate categorization of uterine smooth muscle neoplasms by light microscopic examination is difficult. Multiple classification schemes have been proposed based on mitotic rate, nuclear atypia, and the presence or absence of necrosis. None of these classification systems has been entirely successful. Multiple ancillary techniques have been tested for their ability to predict behavior of uterine smooth muscle tumors.
OBJECTIVE: We assayed 45 smooth muscle neoplasms for a variety of proliferation markers, oncogene protein products, and DNA ploidy level to determine if these markers supplied prognostically useful information over and above that obtained by routine light microscopic assessment. STUDY
DESIGN: Forty-five uterine smooth muscle neoplasms were assessed for DNA ploidy; silver-staining nucleolar organizer regions (AgNORs); percent nuclear proliferating cell nuclear antigen (PCNA); expression of p53, Her-2/neu, and MDM-2 protein; mitotic rate; and nuclear grade. These markers were correlated with histologic diagnosis and the occurrence of a clinically adverse event (death, metastasis, or recurrence).
RESULTS: Diagnostic category (P <.001), nuclear grade (P <.002), mitotic activity (P <.001), mean AgNORs (P <.001), percent nuclear PCNA (P =.02), and expression of p53 (P =.02) all correlated with clinical outcome. No statistically significant correlation between clinical outcome and the categories MDM-2 expression, Her-2/neu expression, or DNA ploidy was seen. Nuclear grade, p53 expression, mitotic rate, AgNORs, and percent nuclear PCNA correlated with diagnosis.
CONCLUSIONS: Diagnostic category, mitotic rate, AgNOR counts, PCNA, and p53 expression dichotomized uterine smooth muscle neoplasms into prognostically favorable and unfavorable groups. Although highly significant, the category AgNORs was no more successful than mitotic rate in dividing uterine smooth muscle neoplasms into prognostically favorable and unfavorable groups. Expression of p53 and percent nuclear PCNA dichotomized uterine smooth muscle neoplasms into prognostic groups, but neither technique reached the level of significance achieved by mitotic rate. Our data indicate that mitotic rate and the classification system of Kempson and Bari are at least as effective as the tested markers in separating uterine smooth muscle neoplasms into prognostic categories.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656730     DOI: 10.5858/2000-124-0221-USMT

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

Authors:  Qing Zhang; Margaux Jenna Kanis; Julianne Ubago; Dachao Liu; Denise M Scholtens; Anna E Strohl; John R Lurain; Shohreh Shahabi; Beihua Kong; Jian-Jun Wei
Journal:  Hum Pathol       Date:  2017-12-16       Impact factor: 3.466

2.  Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Authors:  Christopher S Hale; Meng Qian; Michelle W Ma; Patrick Scanlon; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Yongzhao Shao; David Polsky; Iman Osman; Farbod Darvishian
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

Review 3.  Epigenomic and enhancer dysregulation in uterine leiomyomas.

Authors:  Oliwia W Mlodawska; Priyanka Saini; J Brandon Parker; Jian-Jun Wei; Serdar E Bulun; Melissa A Simon; Debabrata Chakravarti
Journal:  Hum Reprod Update       Date:  2022-06-30       Impact factor: 17.179

4.  A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors.

Authors:  Lea Rath-Wolfson; Yevgenia Rosenblat; Marisa Halpern; M Herbert; I Hammel; Rivka Gal; M Leabu; Rumelia Koren
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

5.  An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center.

Authors:  Ulaş Solmaz; Levent Dereli; Gülşah Selvi Demirtaş; Atalay Ekin; Emre Mat; Cenk Gezer; Pınar Solmaz Hasdemir; Sevil Sayhan; Muzaffer Sancı; Niyazi Aşkar
Journal:  Turk J Obstet Gynecol       Date:  2015-09-15

Review 6.  The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.

Authors:  Piotr Rubisz; Michał Ciebiera; Lidia Hirnle; Magdalena Zgliczyńska; Tomasz Łoziński; Piotr Dzięgiel; Christopher Kobierzycki
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

7.  Clinical and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single-center retrospective study.

Authors:  Chengcheng Ning; Lihong Zhang; Chenyan Zhao; Xiaojun Chen; Xiaoxia Liu; Chao Gu
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

Review 8.  Potential Therapeutic Targets in Uterine Sarcomas.

Authors:  Tine Cuppens; Sandra Tuyaerts; Frédéric Amant
Journal:  Sarcoma       Date:  2015-10-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.